Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley Sells 52,636 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Exelixis Price Performance

EXEL opened at $37.53 on Thursday. The firm has a 50 day simple moving average of $34.34 and a 200 day simple moving average of $31.50. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $37.64. The company has a market cap of $10.50 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Hedge Funds Weigh In On Exelixis

Several institutional investors have recently modified their holdings of EXEL. Coppell Advisory Solutions LLC acquired a new position in Exelixis during the fourth quarter valued at approximately $25,000. Colonial Trust Co SC grew its holdings in shares of Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 765 shares during the period. USA Financial Formulas bought a new stake in shares of Exelixis in the 4th quarter valued at $32,000. Principal Securities Inc. raised its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after buying an additional 373 shares during the period. Finally, Kestra Investment Management LLC bought a new position in Exelixis during the fourth quarter worth about $39,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EXEL has been the topic of a number of research analyst reports. UBS Group raised their target price on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Brookline Capital Management started coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating on the stock. Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. Guggenheim reissued a “buy” rating and issued a $42.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Finally, Stephens restated an “equal weight” rating and set a $29.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average target price of $37.24.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.